Compare · NVO vs SEPN
NVO vs SEPN
Side-by-side comparison of Novo Nordisk A/S (NVO) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $199.97B, about 114.6x SEPN ($1.74B).
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 11 for SEPN).
- Company
- Novo Nordisk A/S
- Septerna Inc.
- Price
- -
- -
- Market cap
- $199.97B
- $1.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SEPN
- SEC Form 3 filed by new insider Patni Rajiv
- SVP, Drug Discovery Long Daniel D. exercised 3,333 shares at a strike of $2.76 and sold $126,078 worth of shares (3,333 units at $37.83) as part of a pre-agreed trading plan (SEC Form 4)
- Septerna to Participate in Upcoming Investor Conferences
- Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
- SEC Form 4 filed by Large owner Third Rock Ventures V, L.P.
- Amendment: SEC Form SCHEDULE 13D/A filed by Septerna Inc.
- Director Ra Capital Management, L.P. sold $63,452,500 worth of shares (1,493,000 units at $42.50) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.
- President and COO Bhatt Elizabeth exercised 25,000 shares at a strike of $5.79 and sold $1,100,000 worth of shares (25,000 units at $44.00) as part of a pre-agreed trading plan (SEC Form 4)